08:36 AM EST, 12/23/2024 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) said Monday it dosed the first patients in a phase 1/2a clinical trial of ARO-INHBE, the company's investigational therapy to counter obesity.

The study will treat patients with ARO-INHBE as monotherapy in part 1 and in combination with tirzepatide in part 2.

The company also recently filed for regulatory clearance to launch a clinical trial of its second obesity candidate, ARO-ALK7.

Shares of the company were up more than 2.5% in Monday's premarket activity.